Design, optimization, and <i>in-vivo</i> hypoglycaemic effect of nanosized glibenclamide for inhalation delivery

Abdel-Rashid, Rania S.; Abd-Allah, Fathy I.; Hassan, Abdelsabour A.; Hashim, Fahima

doi:10.1080/08982104.2020.1806874

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, 1 mL of chloroquine-loaded niosomes was placed in a dialysis bag and immersed in 100 mL dissolution medium (PBS) adjusted to mimic lungs lining pH of ca. 6.9 [ 19 ], under stirring at 37 °C. At specified time intervals, 1 mL aliquots were withdrawn and replaced with an equal volume of fresh release medium.…”

Section: Methodsmentioning

confidence: 99%

Intratracheal Administration of Chloroquine-Loaded Niosomes Minimize Systemic Drug Exposure

et al. 2021

View full text Add to dashboard Cite

Pulmonary administration provides a useful alternative to oral and invasive routes of administration while enhancing and prolonging the accumulation of drugs into the lungs and reducing systemic drug exposure. In this study, chloroquine, as a model drug, was loaded into niosomes for potential pulmonary administration either via dry powder inhalation or intratracheally. Chloroquine-loaded niosomes have been prepared and extensively characterized. Furthermore, drug-loaded niosomes were lyophilized and their flowing properties were evaluated by measuring the angle of repose, Carr’s index, and Hausner ratio. The developed niosomes demonstrated a nanosized (100–150 nm) spherical morphology and chloroquine entrapment efficiency of ca. 24.5%. The FT-IR results indicated the incorporation of chloroquine into the niosomes, whereas in vitro release studies demonstrated an extended-release profile of the drug-loaded niosomes compared to the free drug. Lyophilized niosomes exhibited poor flowability that was not sufficiently improved after the addition of lactose or when cryoprotectants were exploited throughout the lyophilization process. In vivo, intratracheal administration of chloroquine-loaded niosomes in rats resulted in a drug concentration in the blood that was 10-fold lower than the oral administration of the free drug. Biomarkers of kidney and liver functions (i.e., creatinine, urea, AST, and ALT) following pulmonary administration of the drug-loaded nanoparticles were of similar levels to those of the control untreated animals. Hence, the use of a dry powder inhaler for administration of lyophilized niosomes is not recommended, whereas intratracheal administration might provide a promising strategy for pulmonary administration of niosomal dispersions while minimizing systemic drug exposure and adverse reactions.

show abstract

Section: Methodsmentioning

confidence: 99%

Intratracheal Administration of Chloroquine-Loaded Niosomes Minimize Systemic Drug Exposure

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition to insulin, other glucose-lowering drugs have similar potential for inhalation. The development and optimization of nanosomes for delivering glibenclamide as a hypoglycemic agent to the lungs in the inhaler dosage form have been reported, and the hypoglycemic effect of this dosage form was evaluated in vivo [ 346 ].…”

Section: Application Of Pulmonary Drug Deliverymentioning

confidence: 99%

Pulmonary inhalation for disease treatment: Basic research and clinical translations

Wang,

Yang

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand?

Abderrahmani

Szunerits

Dalle

et al. 2022

Nanotechnology for Diabetes Management

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is the most prominent form of diabetes worldwide. In the history of T2D, insulin resistance of liver, muscle and adipose tissue first develops with no apparent clinical signs. Hyperglycemia ensues when β-cells fail to release a sufficient insulin level into the bloodstream to compensate for insulin resistance. For lowering glycemia, the current therapeutic arsenal includes insulin sensitizers, insulin secretagogues, inhibitors of glucose absorption and reabsorption and ultimately insulin injection. The poor bioavailability and stability, as well as the mode of administration, reduce the long-term efficiency of these drugs, thereby contributing to the dramatic progression of the disease toward disabilities and early mortality risk. This chapter deals with the possible approaches offered by nanotechnology for improving the bioavailability, stability and delivery mode of the current antidiabetic drugs. Improvements provided by nanotechnology could hold promise for implementing a personalized diabetes medicine, as a key to halting the devastating damage caused by this disease.

show abstract

Design, optimization, and in-vivo hypoglycaemic effect of nanosized glibenclamide for inhalation delivery

Cited by 3 publications

References 33 publications

Intratracheal Administration of Chloroquine-Loaded Niosomes Minimize Systemic Drug Exposure

Intratracheal Administration of Chloroquine-Loaded Niosomes Minimize Systemic Drug Exposure

Pulmonary inhalation for disease treatment: Basic research and clinical translations

Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand?

Contact Info

Product

Resources

About